LC
ACAD icon

Landaas & Company’s Acadia Pharmaceuticals ACAD Stock Holding History

Landaas & Company’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-150
Closed -$2K – 61
2018
Q2 		$2K Buy
+150
New +$2.67K ﹤0.01% 319
2018
Q1 		– Sell
-150
Closed -$5K – 54
2017
Q4 		$5K Hold
150
– – ﹤0.01% 284
2017
Q3 		$6K Buy
+150
New +$4.88K 0.01% 275

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Landaas & Company's ACAD Position: Q3 2018 in Review

Landaas & Company sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 150 shares — an estimated $2K sold.

Landaas & Company first reported a position in ACAD in Q3 2017 and held it in 3 quarters. The position peaked at $6K in Q3 2017. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

  • Landaas & Company reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Landaas & Company sold 150 Acadia Pharmaceuticals shares in Q3 2018, an estimated $2K.
  • Landaas & Company first reported a position in Acadia Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Landaas & Company's Acadia Pharmaceuticals position peaked at $6K in Q3 2017.
  • 184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on Landaas & Company's 13F filing for Q3 2018, filed 14 Nov 2018.